These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34982445)

  • 41. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
    Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Colebatch AN; Marks JL; Edwards CJ
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tocilizumab for rheumatoid arthritis.
    Singh JA; Beg S; Lopez-Olivo MA
    Cochrane Database Syst Rev; 2010 Jul; (7):CD008331. PubMed ID: 20614469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Meta-analysis of RCT studies on clinical efficacy of single administration of Tripterygium Glycosides Tablets or combined administration with methotrexate against rheumatoid arthritis].
    Chen WJ; Li TX; Wang XY; Xue ZP; Lyu C; Li HZ; Li YQ; Fan YF; Tian YG; Yang J; Guo MQ; Wang JX; Wu HY; Zhang YQ; Lin N
    Zhongguo Zhong Yao Za Zhi; 2020 Feb; 45(4):791-797. PubMed ID: 32237478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Kynaston-Pearson FJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007649. PubMed ID: 25231904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial.
    Bresnihan B; Newmark R; Robbins S; Genant HK
    J Rheumatol; 2004 Jun; 31(6):1103-11. PubMed ID: 15170922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
    Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Gálvez Muñoz JG; Saiz Cuenca ES; Fry-Smith A
    Cochrane Database Syst Rev; 2011 Feb; (2):CD007649. PubMed ID: 21328299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation.
    Ramírez J; Cañete JD
    Expert Opin Drug Saf; 2018 Jul; 17(7):727-732. PubMed ID: 29883212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Wiśniewska N; Pilc A
    Clin Rheumatol; 2013 Oct; 32(10):1415-24. PubMed ID: 23877486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.
    Bredemeier M; Campos GG; de Oliveira FK
    Clin Rheumatol; 2015 Oct; 34(10):1801-5. PubMed ID: 26070536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
    Salliot C; Dougados M; Gossec L
    Ann Rheum Dis; 2009 Jan; 68(1):25-32. PubMed ID: 18203761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.